| Literature DB >> 29875325 |
Balázs Csóka1, Zoltán H Németh1,2,3, Ildikó Szabó4, Daryl L Davies5, Zoltán V Varga6, János Pálóczi6, Simonetta Falzoni7, Francesco Di Virgilio7, Rieko Muramatsu8, Toshihide Yamashita8, Pál Pacher6, György Haskó1.
Abstract
The macrophage is a major phagocytic cell type, and its impaired function is a primary cause of immune paralysis, organ injury, and death in sepsis. An incomplete understanding of the endogenous molecules that regulate macrophage bactericidal activity is a major barrier for developing effective therapies for sepsis. Using an in vitro killing assay, we report here that the endogenous purine ATP augments the killing of sepsis-causing bacteria by macrophages through P2X4 receptors (P2X4Rs). Using newly developed transgenic mice expressing a bioluminescent ATP probe on the cell surface, we found that extracellular ATP levels increase during sepsis, indicating that ATP may contribute to bacterial killing in vivo. Studies with P2X4R-deficient mice subjected to sepsis confirm the role of extracellular ATP acting on P2X4Rs in killing bacteria and protecting against organ injury and death. Results with adoptive transfer of macrophages, myeloid-specific P2X4R-deficient mice, and P2rx4 tdTomato reporter mice indicate that macrophages are essential for the antibacterial, antiinflammatory, and organ protective effects of P2X4Rs in sepsis. Pharmacological targeting of P2X4Rs with the allosteric activator ivermectin protects against bacterial dissemination and mortality in sepsis. We propose that P2X4Rs represent a promising target for drug development to control bacterial growth in sepsis and other infections.Entities:
Keywords: Cell Biology; Innate immunity
Mesh:
Substances:
Year: 2018 PMID: 29875325 PMCID: PMC5997389 DOI: 10.1172/jci.insight.99431
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708